Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 18, 2024; 14(2): 90571
Published online Jun 18, 2024. doi: 10.5500/wjt.v14.i2.90571
Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation
Gabriel Lazzarotto-da-Silva, Leandro A Scaffaro, Mauricio Farenzena, Lucas Prediger, Rafaela K Silva, Flávia Heinz Feier, Tomaz J M Grezzana-Filho, Pablo D Rodrigues, Alexandre de Araujo, Mario Reis Alvares-da-Silva, Roberta C Marchiori, Cleber Rosito Pinto Kruel, Marcio Fernandes Chedid
Gabriel Lazzarotto-da-Silva, Lucas Prediger, Rafaela K Silva, Flávia Heinz Feier, Tomaz J M Grezzana-Filho, Pablo D Rodrigues, Cleber Rosito Pinto Kruel, Marcio Fernandes Chedid, Department of Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil
Leandro A Scaffaro, Mauricio Farenzena, Department of Interventional Radiology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil
Alexandre de Araujo, Mario Reis Alvares-da-Silva, Roberta C Marchiori, Department of Gastroenterology and Hepatology, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Brazil
Author contributions: Lazzarotto-da-Silva G and Chedid MF participated in the research design, data collection, data analysis, and writing of the manuscript; Scaffaro LA, Farenzena M, Feier FH, Grezzana-Filho TJM, Rodrigues PD, de Araujo A, Alvares-da-Silva MR, Marchiori RC, and Kruel CRP participated in the research design and revision of the final version of the manuscript; Prediger L and Silva RK participated in data collection and writing of the manuscript.
Supported by Financiamento e Incentivo à Pesquisa (FIPE/HCPA) of Hospital de Clínicas de Porto Alegre, No. 2020-0473.
Institutional review board statement: This study complies with ethical standards and was approved by the Hospital de Clínicas de Porto Alegre Institutional Review Board, No: CAAE 37950720.9.0000.5327.
Informed consent statement: Informed consent was waived by the ethics committee because this was an observational retrospective study.
Conflict-of-interest statement: All authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marcio Fernandes Chedid, MD, MSc, PhD, Professor, Department of Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Porto Alegre 90035-007, Brazil. mchedid@hcpa.edu.br
Received: December 7, 2023
Revised: February 12, 2024
Accepted: April 3, 2024
Published online: June 18, 2024
Processing time: 189 Days and 21.4 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is an aggressive malignant neoplasm, and the treatment of choice is liver transplantation (LT). Because the waiting time is often unpredictable, locoregional therapy is used to halt HCC progression until an organ is available. Although largely replaced by transarterial chemoembolization (TACE), transarterial embolization (TAE) or bland embolization is an alternative with a lower cost and safer adverse event profile. Our findings, in conjunction with those of previous studies, provide evidence of non-superiority of TACE over TAE, thereby encouraging a more liberal use of TAE for bridging HCC to LT.